Abstract

Trisomy of chromosome 21, the genetic cause of Down syndrome, has the potential to alter expression of genes on chromosome 21, as well as other locations throughout the genome. These transcriptome changes are likely to underlie the Down syndrome clinical phenotypes. We have employed RNA-seq to undertake an in-depth analysis of transcriptome changes resulting from trisomy of chromosome 21, using induced pluripotent stem cells (iPSCs) derived from a single individual with Down syndrome. These cells were originally derived by Li et al, who genetically targeted chromosome 21 in trisomic iPSCs, allowing selection of disomic sibling iPSC clones. Analyses were conducted on trisomic/disomic cell pairs maintained as iPSCs or differentiated into cortical neuronal cultures. In addition to characterization of gene expression levels, we have also investigated patterns of RNA adenosine-to-inosine editing, alternative splicing, and repetitive element expression, aspects of the transcriptome that have not been significantly characterized in the context of Down syndrome. We identified significant changes in transcript accumulation associated with chromosome 21 trisomy, as well as changes in alternative splicing and repetitive element transcripts. Unexpectedly, the trisomic iPSCs we characterized expressed higher levels of neuronal transcripts than control disomic iPSCs, and readily differentiated into cortical neurons, in contrast to another reported study. Comparison of our transcriptome data with similar studies of trisomic iPSCs suggests that trisomy of chromosome 21 may not intrinsically limit neuronal differentiation, but instead may interfere with the maintenance of pluripotency.

Highlights

  • Down Syndrome (DS) results from an extra copy of chromosome 21, and this change in gene dosage has been proposed to alter chromosome 21 gene expression

  • Cortical neuronal cultures were derived from the induced pluripotent stem cells (iPSCs) following the procedure of Espuny-Camacho et al [16] with minor modifications and harvested after 40 days in culture

  • The iPSC data was generated from 3 independent preps of trisomic clone C2, and 3 independent preps of disomic sub-clones derived from the C2 lineage

Read more

Summary

Introduction

Down Syndrome (DS) results from an extra copy of chromosome 21, and this change in gene dosage has been proposed to alter chromosome 21 gene expression. March 27, 2018 addition to the possible perturbation of specific cellular pathways by altered expression of chromosome 21 genes, chromosome 21 contains genes that impact the global transcriptome directly. These include ADARB1, encoding one of two genes responsible for adenosineto-inosine RNA editing [2]; U2AF1, a constitutive splicing factor [3]; and DYRK1A, a kinase known to target splicing factors [4]. Identifying transcriptome changes reproducibly caused by chromosome 21 trisomy may be crucial to understanding the origins of the clinical features of Down Syndrome

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.